Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: A randomized trial

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 9, 2003, Pages 1671-1676

  Oger, Emmanuel ^a,c   Alhenc Gelas, Martine ^b   Lacut, Karine ^a   Blouch, Marie Thérèse ^a   Roudaut, Nathalie ^a   Kerlan, Véronique ^a   Collet, Michel ^a   Abgrall, Jean François ^a   Aiach, Martine ^b   Scarabin, Pierre Yves ^b   Mottier, Dominique ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

^b INSERM   (France)

^c DANDENONG HOSPITAL   (Australia)

Author keywords

APC resistance; Blood coagulation; Factor V; Hormone replacement therapy; Randomized trial

Indexed keywords

ACTIVATED PROTEIN C; ESTRADIOL; ESTROGEN; PROGESTERONE; PROTHROMBIN; THROMBIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; ESTROGEN THERAPY; FEMALE; HUMAN; HUMAN EXPERIMENT; PARTIAL THROMBOPLASTIN TIME; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ESTROGENS; FEMALE; HUMANS; POSTMENOPAUSE; PROGESTERONE; PROTEIN C;

EID: 10744233448     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000087141.05044.1F     Document Type: Article

References (37)

1. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348:981-983.
2. Oger E, Scarabin PY. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging. 1999;14:55-61.
3. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-980.
4. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983-987.
5. Perez-Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque OA. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 1997;314:796-800.
6. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol. 1998;147:387-390.
7. Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population-based case-control study. Thromb Haemost. 1999;82:1218-1221.
8. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689-696.
9. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2000;84:961-967.
10. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 1992;68:392-395.
11. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997;17:3071-3078.
12. Valk-de Roo GW, Stehouwer CD, Meijer P, Mijatovic V, Kluft C, Kenemans P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol. 1999;19:2993-3000.
13. van Baal WM, Emeis JJ, van der Mooren MJ, Kessel H, Kenemans P, Stehouwer CD. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? a randomised, placebo-controlled 12-week study. Thromb Haemost. 2000;83:29-34.
14. Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsopoulos D, Liang YL, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol. 2000;20:1404-1409.
15. Oger E, Scarabin PY. Hormone replacement therapy and risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol. 1999;149:292-293. Letter.
16. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
17. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999;130:643-650.
18. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ. De Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
19. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 1999;93:1271-1276.
20. Lowe GD, Rumley A, Woodward M, Reid E. Oral contraceptives and venous thromboembolism. Lancet. 1997;349:1623.
21. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DJ, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein: a cross-sectional population survey. Thromb Haemost. 2001;86:550-556.
22. Thomassen MC, Curvers J, Rimmer JE, Preston FE, van Wersch JW, Tans G, et al. Influence of hormone replacement therapy, oral contraceptives and pregnancy on APC resistance. XVIIth Congress of the ISTH, August 14-21, 1999, Washington, DC. Abstract.
23. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol. 2001;115:415-420.
24. Curvers J, Thomassen MC, Nicolaes GA, van Oerle R, Hamulyak K, Hemker HC, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol. 1999;105:88-94.
25. Curvers J, Christella M, Thomassen LG, De Ronde H, Bertina RM. Rosendaal FR, et al. Effects of pre-analytical variables on activated protein C resistance determined via a thrombin generation-based assay. Thromb Haemost. 2002;87:483-492.
26. Leroyer C, Mercier B, Escoffre M, Ferec C, Mottier D. Factor V Leiden prevalence in venous thromboembolism patients. Chest. 1997;111:1603-1606.
27. Hahn L, Mattsson LA, Andersson B, Tengborn L. The effects of oestrogen replacement therapy on haemostatic variables in postmenopausal women with non-insulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis. 1999;10:81-86.
28. Gottsater A, Rendell M, Hulthen UL, Berntorp E, Mattiasson I. Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med. 2001;249:237-246.
29. Nicolaes GA, Thomassen MC, Tans G, Rosing J, Hemker HC. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagul Fibrinolysis. 1997;8:28-38.
30. Demirol A, Baykal C, Kirazli S, Ayhan A. Effects of hormone replacement on hemostasis in spontaneous menopause. Menopause. 2001;8:135-140.
31. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84:15-21.
32. Hoibraaten E, Os I, Seljeflot I, Andersen TO, Hofstad A, Sandset PM. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study. Thromb Res. 2000;98:19-27.
33. Marque V, Alhenc-Gelas M, Plu-Bureau G, Oger E, Scarabin PY. The effects of transdermal and oral/progesterone regimens on free and total protein S in postmenopausal women. Thromb Haemost. 2001;86:713-714.
34. Risks and benefits of estrogen plus progesfin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
35. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost. 2001;85:619-625.
36. Tans G, Rosendaal FR, Curvers J, Thomassen MC, Bertina RM, Rosing J. APC resistance determined with the endogenous thrombin generation potential is associated with venous thrombosis: a blinded clinical evaluation. Thromb Haemost. 1999;82:202-203.
37. De Mitrio V, Marino R, Giannoccaro F, Galantino P, Cicinelli E. Improved sensitivity to activated protein C following postmenopausal hormone replacement therapy. Blood Coagul Fibrinolysis. 1998;9:293-294. Letter.